Physician profile
William Levis
NPI 1265512164
$768.47
in general payments reported to CMS, 2019-2025
11 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.89 · 2021: $76.76 · 2022: $89.75 · 2023: $111 · 2024: $371 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.07 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $333.48 | 2022-2025 | Stelara, Tremfya, Remicade |
| Abbvie INC. | $125.88 | 2021-2025 | |
| Celgene Corporation | $108.74 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $69.94 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.32 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $28.54 | 2024 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.25 | 2023 | Trulance |
| Nestle Healthcare Nutrition INC. | $16.97 | 2021 | |
| Vivus LLC | $15.04 | 2021 | |
| Endogastric Solutions, INC | $4.31 | 2024 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$62,081.09 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Levis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.